Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Mawer Investment Management Ltd.

Mawer Investment Management Ltd. reduced its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 44.4% in the third quarter, according to its most recent filing with the SEC. The fund owned 40,860 shares of the medical research company's stock after selling 32,693 shares during the quarter. Mawer Investment Management Ltd. owned about 0.08% of Charles River Laboratories International worth $8,048,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of CRL. QRG Capital Management Inc. bought a new stake in Charles River Laboratories International during the first quarter worth approximately $284,000. Vanguard Group Inc. boosted its stake in shares of Charles River Laboratories International by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 6,046,467 shares of the medical research company's stock worth $1,638,290,000 after purchasing an additional 66,161 shares during the period. O Shaughnessy Asset Management LLC bought a new position in Charles River Laboratories International during the 1st quarter valued at about $415,000. UniSuper Management Pty Ltd raised its position in Charles River Laboratories International by 452.1% in the 1st quarter. UniSuper Management Pty Ltd now owns 4,003 shares of the medical research company's stock worth $1,085,000 after purchasing an additional 3,278 shares during the period. Finally, Bessemer Group Inc. lifted its stake in Charles River Laboratories International by 456.6% in the first quarter. Bessemer Group Inc. now owns 8,649 shares of the medical research company's stock worth $2,343,000 after purchasing an additional 7,095 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Stock Down 0.1 %

CRL stock traded down $0.24 during trading on Monday, reaching $187.50. 777,845 shares of the company traded hands, compared to its average volume of 625,273. The company has a market capitalization of $9.59 billion, a price-to-earnings ratio of 23.50, a price-to-earnings-growth ratio of 4.84 and a beta of 1.38. Charles River Laboratories International, Inc. has a 12 month low of $176.48 and a 12 month high of $275.00. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The business has a 50 day simple moving average of $195.26 and a 200 day simple moving average of $207.19.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. During the same quarter in the prior year, the business posted $2.72 EPS. The business's revenue for the quarter was down 1.6% compared to the same quarter last year. On average, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 10.19 earnings per share for the current fiscal year.

Charles River Laboratories International announced that its Board of Directors has approved a share buyback program on Wednesday, August 7th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the medical research company to reacquire up to 9.6% of its shares through open market purchases. Shares buyback programs are often an indication that the company's board believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Baird R W downgraded Charles River Laboratories International from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 8th. TD Cowen lifted their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a "hold" rating in a research report on Monday, November 11th. UBS Group upped their price target on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Evercore ISI lifted their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an "in-line" rating in a report on Thursday, November 7th. Finally, StockNews.com downgraded shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a research note on Thursday, November 7th. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of "Hold" and an average target price of $214.38.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the firm's stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the transaction, the director now owns 12,386 shares of the company's stock, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.30% of the company's stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).